Trials / Active Not Recruiting
Active Not RecruitingNCT02846987
Study of Abemaciclib in Dedifferentiated Liposarcoma
Phase 2 Study of Abemaciclib (LY2835219) in Dedifferentiated Liposarcoma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test any good and bad effects of the study drug called Abemaciclib. Abemaciclib could shrink your cancer but it could also cause side effects. Researchers hope to learn if the study drug will delay the growth of the cancer or shrink the cancer by at least one quarter compared to its present size. Abemaciclib is not FDA approved and has not been tested in liposarcoma, but it has shrunk tumors in patients with breast cancer, lymphoma, and lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abemaciclib |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2026-07-01
- Completion
- 2026-07-01
- First posted
- 2016-07-27
- Last updated
- 2025-06-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02846987. Inclusion in this directory is not an endorsement.